Back to top

Stoke Therapeutics (STOK) Gets a Buy from Canaccord Genuity

In a report released yesterday, Sumant Kulkarni from Canaccord Genuity reiterated a Buy rating on Stoke Therapeutics, with a price target of $58.00...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Stoke Therapeutics, Inc. (STOK)